关于ECMO作为移植的桥梁的叙述性审查:优化心脏和肺衰竭的结果
Pragnya Bandari1, Yezen M H Alnasiri2, Amna Ahsan3
1Medicine, Malla Reddy Medical College for Women, Hyderabad, IND.
Cureus
|February 4, 2026
概括
体外膜氧化 (ECMO) 对心脏和肺移植候选人至关重要. 最佳的患者选择和早期干预显著提高了生存率,但对其使用的标准化对于更好的结果至关重要.
科学领域:
- 心脏病学 心脏病学
- 肺部病理学 肺部病理学
- 移植医学 移植医学
背景情况:
- 身体外膜氧化 (ECMO) 提供临时的心肺支,用于最终阶段的心脏和肺衰竭.
- 它作为移植桥梁的使用正在扩大,需要对其对移植资格和结果的影响进行审查.
研究的目的:
- 评估目前关于ECMO作为通往心脏和肺移植的桥梁的证据.
- 概述选择标准,分析干预时间,总结生存和并发症数据,并确定标准化的局限性.
主要方法:
- 在过去15年内发表的PubMed和Rayyan的英语研究的叙事评论.
- 搜索术语包括"ECMO"",心力衰竭"和"肺衰竭".
- 儿童和非英语研究被排除在外.
主要成果:
- 患者的选择以诸如多器官功能障碍和晚年等禁忌为指导.
- 早期ECMO启动与改善的生存率有关.
- 并发症包括功能衰竭,出血,感染和血管问题;长时间的桥梁影响结果.
结论:
- ECMO是心脏和肺移植的关键桥梁.
- 有效性取决于精确的患者选择,早期/标准化启动和统一的指导方针.
- 标准化和一致的报告对于优化结果和移植后证据至关重要.
相关概念视频
Heart Failure II: Pathophysiology
948
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
948
Pathophysiology of Heart Failure
3.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.7K
Heart Failure I: Introduction
903
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
903
Heart Failure VI: Adjunct Therapies
348
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
348
Heart Failure Drugs: Diuretics
981
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
981
Heart Failure V: Medical Management
329
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
329


